OH · State regulatory reference
Ohio.
Restrictive
Ohio's distinctive signal is aggressive Board of Pharmacy enforcement on peptide and GLP-1 compounding at prescriber clinics and med spas — not telehealth. In its own guidance, the Board states that since the beginning of 2025 it has summarily suspended more than 30 clinics and med spas after finding clear and convincing evidence of danger of immediate harm, and its July 2025 GLP-1 guidance holds that research-only peptides such as retatrutide and cagrilintide cannot be compounded under state or federal law. Individual board orders name retatrutide directly (e.g. the Slimbolic and Ageless Medica summary suspensions). Telehealth itself is comparatively open under ORC 4743.09.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
ORC 4743.09 permits establishing a patient relationship and prescribing during an initial telehealth visit (synchronous or asynchronous) if the standard of care equals in-person care; controlled substances carry added limits under OAC 4731-11-09.
Compounding
The Board's July 2025 GLP-1 guidance bars compounding 'copies' of semaglutide and tirzepatide now that both are off the FDA shortage list, and prohibits retatrutide and cagrilintide outright as research-only substances with no USP monograph. Revised OAC 4729:7-1-01 adopts USP <795>/<797> (2023 versions), with enforcement beginning February 28, 2027.
Sources
- 01 Ohio Board of Pharmacy — 'Ten Common Prescriber Clinic and Medical Spa Violations' (updated Dec. 8, 2025; 30+ summary suspensions in 2025) ↗
- 02 Ohio Board of Pharmacy — 'Compounding of GLP-1 Drug Products in Ohio' guidance (July 17, 2025) ↗
- 03 Ohio Revised Code 4743.09 (telehealth standard of care; initial visit via telehealth) ↗
- 04 Ohio Administrative Code 4729:7-2-01 (pharmacy compounding definitions) ↗